Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
The cash and debt free consideration value is €370 million.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated
